True or false: Tazemetostat has demonstrated durable activity in patients with relapsed/refractory FL and mutations in EZH2.
Rituximab maintenance therapy significantly prolonged PFS in patients with newly diagnosed FL given R-CHOP versus rituximab plus bendamustine, according to data presented at ASH 2020.
The _______ study established that 2 years of rituximab maintenance therapy after first-line immunochemotherapy significantly improves PFS in patients with FL.
True or False: Among patients with FL, MRD-negativity led to significantly reduced OS.
Long-term follow-up results from the PRIMA study confirm that rituximab maintenance after induction immunochemotherapy improves PFS in patients with FL.
Findings from which clinical trial suggest that obinutuzumab- and rituximab-based chemo yield similar lymphoma-related symptoms and health-related QoL improvements in treatment-naïve FL?
True or false: Tazemetostat is not FDA-approved for relapsed/refractory follicular lymphoma.
True or False: No link exists between achieving a PET-CT complete metabolic response after first line immunochemotherapy and improved survival outcomes in FL.